John A Kollins's Net Worth
$189 Thousand
Who is John A Kollins?
John A Kollins does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include OXIGENE INC, Satsuma Pharmaceuticals, Inc., and Transcept Pharmaceuticals Inc.
SEC CIK
John A Kollins's CIK is 0001391070
Past Insider Trading and Trends
2013 was John A Kollins's most active year for acquiring shares with 2 total transactions. John A Kollins's most active month to acquire stocks was the month of December. 2023 was John A Kollins's most active year for disposing of shares, totalling 8 transactions. John A Kollins's most active month to dispose stocks was the month of May. 2014 saw John A Kollins paying a total of $89,827.67 for 4,161 shares, this is the most they've acquired in one year. In 2023 John A Kollins cashed out on 1,885,483 shares for a total of $278,379.01, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
OXIGENE INC (OTLC) Snapshot price: $0.02296
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Satsuma Pharmaceuticals, Inc. No price found
President and CEOJohn A Kollins used to own units in Common Stock, $0.0001 par value but no longer holds any shares there. In the year 2019 John A Kollins disposed a total of 305,911 shares of Satsuma Pharmaceuticals, Inc. equalling to $278,379.01.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -305.91K |
$0.91 | -$278,379.01 |
0
|
Jun 6 - Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Transcept Pharmaceuticals Inc No price found
SVP, Chief Business OfficerJohn A Kollins owns 4,161 units of Common Stock. In the year 2012 John A Kollins filed a total of 6 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 4.16K |
$21.59 | $89,827.67 | 4.16K |
Oct 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||